ArticleScientific reports2025
Coagulation profiles of breast cancer patients attending at cancer treatment centres in Northwest Ethiopia 2023: a comparative cross-sectional study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cytogenetic alterations and coagulopathy in breast cancer patients: molecular mechanisms and clinical implications.Annals of medicine and surgery (2012) · 2026Review
- The Plasma Glycoprotein Milieu in the Hemato-Oncological Patient Inhibits Platelet Function.Biomolecules · 2026Article
- Thrombopoiesis meets tumorigenesis: unlocking the diagnostic and prognostic potential of platelet indices in breast cancer- a narrative review.Annals of medicine and surgery (2012) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the primary cause of cancer-related deaths in women, especially in developing nations where early detection and comorbidity management are challenging. Coagulopathy significantly enhance the disease severity, but its impact on Ethiopian patients is unclear. Therefore, this study aims to investigate and compare coagulation profiles in chemotherapy-experienced, chemotherapy-naive breast cancer patients, and healthy controls. An Institutional-based comparative cross-sectional study was conducted at the University of Gondar and Felege Hiwot Comprehensive Specialized Hospitals from 15 May 2023 to 30 August 2023 on a total of 180 participants. Participants socio-demographic and clinical data were collected using structured questionnaires in face-to-face interviews and medical record reviews. Blood sample for laboratory tests were taken, with 3 ml in ethylenediaminetetraacetic acid, 3 ml in trisodium citrate, and 2 ml in serum separator tubes. Coagulation parameters were measured using Genrui coagulation analyser (CA51) and Sysmex KX-21 hematology analyser. Data entry was done using Epi Data version 4.6 and transform to SPSS version 25 for analysis then descriptive statistics was presenting with tables. One-way ANOVA and Kruskal-Wallis tests were used to compare coagulation parameters among the three study groups, considering normal and skewed data, respectively. The activated partial thromboplastin time in chemotherapy-experienced, chemotherapy-naïve patients, and healthy controls showed median ± IQR values of 34.3 ± 15.8, 35 ± 13.3, and 29.2 ± 5.9 s, respectively, indicating a significant difference (p: 0.016). Similarly, the prothrombin time in the same groups had median ± IQR values of 15 ± 3.9, 15.3 ± 2.9, and 13.2 ± 1.9 s, respectively, with a significant difference (p < 0.001). Platelet count mean ± SD in chemotherapy-experienced, chemotherapy-naïve patients, and healthy controls were 351.3 ± 99.6, 345.6 ± 117.5, and 284.3 ± 79.3, respectively, showing a significant difference (p < 0.001). The mean ± SD of mean platelet volume in the same groups were 10.4 ± 2.7, 9.5 ± 2.4, and 9 ± 1.2, respectively, with a significant difference (p: 0.003). Coagulation parameters of both chemotherapy-experienced and chemotherapy-naïve patients were abnormally prolonged compared to healthy controls. This event indicates in vivo coagulation and it may increase bleeding tendency in patients. Therefore, early laboratory investigation of the coagulation profiles of breast cancer patients is critical for early detection and intervention of the coagulopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.